American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer.
نویسندگان
چکیده
PURPOSE To develop a guideline to improve the accuracy of human epidermal growth factor receptor 2(HER2) testing in invasive breast cancer and its utility as a predictive marker. METHODS The American Society of Clinical Oncology and the College of American Pathologists convened an expert panel, which conducted a systematic review of the literature and developed recommendations for optimal HER2 testing performance. The guideline was reviewed by selected experts and approved by the board of directors for both organizations. RESULTS Approximately 20% of current HER2 testing may be inaccurate. When carefully validated testing is performed, available data do not clearly demonstrate the superiority of either immunohistochemistry(IHC) or in situ hybridization (ISH) as a predictor of benefit from anti-HER2 therapy. RECOMMENDATIONS The panel recommends that HER2 status should be determined for all invasive breast cancer. A testing algorithm that relies on accurate, reproducible assay performance, including newly available types of brightfield ISH, is proposed. Elements to reliably reduce assay variation (for example, specimen handling, assay exclusion, and reporting criteria) are specified. An algorithm defining positive, equivocal, and negative values for both HER2 protein expression and gene amplification is recommended: a positive HER2 result is IHC staining of 3 + (uniform, intense membrane staining of 30% of invasive tumor cells), a fluorescent in situ hybridization (FISH) result of more than six HER2 gene copies per nucleus or a FISH ratio (HER2 gene signals to chromosome 17 signals) of more than 2.2; a negative result is an IHC staining of 0 or 1 +, a FISH result of less than 4.0 HER2 gene copies per nucleus, or FISH ratio of less than 1.8. Equivocal results require additional action for final determination. It is recommended that to perform HER2 testing, laboratories show 95% concordance with another validated test for positive and negative assay values. The panel strongly recommends validation of laboratory assay or modifications, use of standardized operating procedures, and compliance with new testing criteria to be monitored with the use of stringent laboratory accreditation standards, proficiency testing, and competency assessment. The panel recommends that HER2 testing be done in a CAP-accredited laboratory or in a laboratory that meets the accreditation and proficiency testing requirements set out by this document.
منابع مشابه
Guideline Summary: American Society of Clinical Oncology/College of American Pathologists Guideline Recommendations for Human Epidermal Growth Factor Receptor HER2 Testing in Breast Cancer.
Context The American Society of Clinical Oncology (ASCO) and the College of American Pathologists (CAP) collaborated to develop an evidence-based guideline for optimal human epidermal growth factor receptor 2 (HER2; also sometimes referred to as c-neu or c-erbB-2) testing performance in invasive breast cancer (J Clin Oncol 25:118-145, 2007). The ASCO/CAP Expert Panel, composed of a range of exp...
متن کاملASCO-CAP guidelines for breast predictive factor testing: an update.
This brief report compares and contrasts the American Society of Clinical Oncology/College of American Pathologists guidelines for breast cancer predictive factor testing including the American Society of Clinical Oncology/College of American Pathologists human epidermal growth factor receptor, type 2, erbB2 Guideline published in 2007 and the recently published Guideline for Estrogen Receptor ...
متن کاملRecommendations for human epidermal growth factor receptor 2 testing in breast cancer: American Society of Clinical Oncology/College of American Pathologists clinical practice guideline update.
PURPOSE To update the American Society of Clinical Oncology (ASCO)/College of American Pathologists (CAP) guideline recommendations for human epidermal growth factor receptor 2 (HER2) testing in breast cancer to improve the accuracy of HER2 testing and its utility as a predictive marker in invasive breast cancer. METHODS ASCO/CAP convened an Update Committee that included coauthors of the 200...
متن کاملPathologists' Guideline Recommendations for Immunohistochemical Testing of Estrogen and Progesterone Receptors in Breast Cancer.
Expression of the hormone receptors (estrogen receptor (ER) and progesterone receptor (PR)) as well as overexpression / amplification of the human epi-dermal growth factor receptor-2 (HER2) have not only been identified as important prognostic factors among patients with breast cancer. They have also been characterized as essential predictive factors for benefit derivable from endocrine treatme...
متن کاملLaboratory Compliance With the American Society of Clinical Oncology/College of American Pathologists Guidelines for Human Epidermal Growth Factor Receptor 2 Testing
N Context.—To ensure quality human epidermal growth receptor 2 (HER2) testing in breast cancer, the American Society of Clinical Oncology/College of American Pathologists guidelines were introduced with expected compliance by 2008. Objective.—To assess the effect these guidelines have had on pathology laboratories and their ability to address key components. Design.—In late 2008, a survey was d...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
عنوان ژورنال:
- Archives of pathology & laboratory medicine
دوره 131 1 شماره
صفحات -
تاریخ انتشار 2007